Andrew Krentz has four decades of clinical and translational research experience in metabolic, endocrine and related cardiovascular disorders. His expertise in the life sciences includes preclinical and early-phase clinical drug development; he has personally contributed translational medical innovations to endocrinology clinical practice. He is actively involved in projects focused on precision diagnostics and therapeutics, digital healthcare, and healthy longevity that bridge the academic-industry spaces. Beyond his expertise in diabetes and endocrinology, he is accredited as a clinical specialist by the European Society for Hypertension and is a member of the Medical, Scientific & Research Committee of Heart UK. He is President-Elect of the Vascular, Lipid & Metabolism section of the Royal Society of Medicine as well as being a member of the European Group for the Study of Insulin Resistance (EGIR) and the Diabetes & Cardiovascular Study Group of the European Association for the Study of Diabetes (EASD). He has authored more than 200 scientific publications and founded the journal Cardiovascular Endocrinology & Metabolism and serves as Editor-in-Chief.

*5 stars* "...comprehensively covers the topic by first addressing the normal physiology of insulin, including biosynthesis, physiologic actions, and nonclassic actions. [Also] cover the role of insulin in diseases in states of excess and resistance, as well as treatment approaches.... [U]seful to all levels of learners including medical students, residents, fellows, and attending physicians as it provides an overview of insulin that would be beneficial to any level of medical learner.... [D]oes an excellent job of first giving a very in-depth overview of the basic biosynthesis and physiology of insulin - which provides the reader with the necessary basis to move forward into the pathophysiology chapters.... [U]ses frequent historical contexts and origin stories which were a nice way to engage by providing context.... [A]n excellent reference, especially for use when coming across patients with gray-area or complex diabetes." --©Doody’s Review Service, 2024, Prathayini Subarajan, DO (Loyola University Stritch School of Medicine)

• Forewordby Steve EdelmanIntroduction and Prefaceby Andre J KrentzSection 1: Normal Physiology: Insulin Secretion and Insulin Action1. Insulin Biosynthesis and Releaseby Gabriela da Silva Xavier 2. Classic Metabolic Actions of Insulin in Humansby Andrew J Krentz 3. Non-classic Effects of Insulinby George KingSection 2a: Role of Insulin in Human Disease4. Type 1 Diabetes Pathogenesis: Lessons Learned and Questions that Remainby Adebola Matthew Giwa, Abdel Hamad, Zahra Omidian, Angela Yang, Neha Majety, Tiffany Jackson, Kusuma Ananth, Mohanraj Sadasivam, Marjan Behzadirad, Thomas Donner and Rizwan Ahmed 5. Insulin Therapy – A Century of Progressby Geremia Bolli 6. Treatment and Prevention of Type 1 Diabetes in the 21st Centuryby Jay S Skylar, David Baidal, and J Sosenko 7. Differentiation of Diabetes by Pathophysiology: A Focus on Insulin Deficiency vs Insulin Resistanceby Adrian Heald Section 2b: Syndromes of Insulin Excess8. Congenital Hyperinsulinismby Katherine Lord and Diva D De Leon 9. Hypoglycemic Disorders in Adultsby Adrian Vella and Maheswaran Dhanasekaran Section 2c: Insulin Resistance in Human Disease10. Obesity and Insulin Resistance: Pathophysiology and Principles of Therapyby Rita Basu 11. The Cardiometabolic Syndrome and Vascular Disease: Pivotal Role of Insulinby Michael D Shapiro, Trevor Caldarera, and Jordan Tannenbaum 12. Insulin, IGF-1, and Cancer: Pathogenic Considerations and Therapeutic Opportunitiesby John Vincent Reynolds and Jessie Andrea Elliott 13. Insulin and Neurodegenerative Diseasesby Heather A Ferris 14. Non-pharmacological, Pharmacological, and Surgical Options for Obesity-related Cardiometabolic Disorders: Metabolic and Clinical Impactby Alexander Dimitri Miras, Mariana Abdel-Malek, and Darmiga Thayabaran 15. Syndromes of Severe Insulin Resistance: Lessons from Natureby Andrew J Krentz